Status:
TERMINATED
Strategies for Assessment of Fluid Overload in Acute Decompensated Heart Failure
Lead Sponsor:
Region Skane
Conditions:
Heart Failure
Decompensated Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Heart failure (HF) is the endstage of all heart disease, characterized by inability of either the left or right heart or both to maintain sufficient output of blood for the demands of the body at norm...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Hospitalization for decompensated heart failure is defined as an event that meets all of the following criteria:
- The patient is admitted to the hospital with a primary diagnosis of HF (previous echo mandatory)
- The patient's length-of-stay in hospital extends for at least 24 hours
- The patient exhibits documented new or worsening symptoms due to HF on presentation, including at least ONE of the following:
- Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal nocturnal dyspnea)
- Decreased exercise tolerance
- Fatigue
- Other symptoms of worsened end-organ perfusion or volume overload (as determined by the medical judgement of the investigator)
- The patient has objective evidence of new or worsening HF, consisting of at least two physical examination findings OR one physical examination finding and at least ONE laboratory criterion, including:
- Physical examination findings considered to be due to heart failure, including new or worsened:
- Peripheral edema
- Increasing abdominal distention or ascites (in the absence of primary hepatic disease)
- Pulmonary rales/crackles/crepitations
- Increased jugular venous pressure and/or hepatojugular reflux
- S3 gallop
- Clinically significant or rapid weight gain thought to be related to fluid retention
- Laboratory evidence of new or worsening HF, if obtained within 24 hours of presentation, including:
- Increased B-type natriuretic peptide (BNP)/ N-terminal pro-BNP (NT-proBNP) concentrations consistent with decompensation of heart failure (such as BNP \> 500 pg/mL or NT-proBNP \> 2,000 pg/mL). In patients with chronically elevated natriuretic peptides, a significant increase should be noted above baseline.
- Radiological evidence of pulmonary congestion
- Non-invasive diagnostic evidence of clinically significant elevated left- or right-sided ventricular filling pressure or low cardiac output. For example, echocardiographic criteria could include: E/e' \> 15 or D-dominant pulmonary venous inflow pattern.
- Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure) ≥ 18 mmHg, central venous pressure ≥ 12 mmHg, or a cardiac index \< 2.2 L/min/m2
- The patient receives initiation or intensification of treatment specifically for HF, including at least one of the following:
- Augmentation in oral diuretic therapy
- Intravenous diuretic or vasoactive agent (e.g., inotrope, vasopressor, or vasodilator)
- Mechanical or surgical intervention, including:
- Mechanical circulatory support (e.g. intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation, total artificial heart)
- Mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis)
- Exclusion Criteria:
- • Acute coronary syndrome, cardiogenic chock
Exclusion
Key Trial Info
Start Date :
April 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04901039
Start Date
April 14 2022
End Date
June 1 2023
Last Update
March 7 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsingborg General Hospital
Helsingborg, Sweden
2
Skåne University Hospital
Lund, Sweden
3
Skåne University Hospital
Malmo, Sweden